Summit Therapeutics is expected to report a Q3 2026 net loss of $0.28 per share on zero revenue, as the stock trades at $21.42 against a bullish consensus price target of $34.50.
Investors are laser-focused on the clinical development progress of ivonescimab, specifically enrollment updates and regulatory timelines for the HARMONi trial programs.
With the company aggressively scaling its global clinical infrastructure, analysts are closely monitoring the quarterly cash burn rate and total R&D investment.
Management's commentary regarding the anticipated timing for a Biologics License Application (BLA) filing in non-small cell lung cancer will be the primary driver of post-earnings sentiment.